Your browser doesn't support javascript.
loading
Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.
Grossman, R L; Abel, B; Angiuoli, S; Barrett, J C; Bassett, D; Bramlett, K; Blumenthal, G M; Carlsson, A; Cortese, R; DiGiovanna, J; Davis-Dusenbery, B; Dittamore, R; Eberhard, D A; Febbo, P; Fitzsimons, M; Flamig, Z; Godsey, J; Goswami, J; Gruen, A; Ortuño, F; Han, J; Hayes, D; Hicks, J; Holloway, D; Hovelson, D; Johnson, J; Juhl, H; Kalamegham, R; Kamal, R; Kang, Q; Kelloff, G J; Klozenbuecher, M; Kolatkar, A; Kuhn, P; Langone, K; Leary, R; Loverso, P; Manmathan, H; Martin, A-M; Martini, J; Miller, D; Mitchell, M; Morgan, T; Mulpuri, R; Nguyen, T; Otto, G; Pathak, A; Peters, E; Philip, R; Posadas, E.
Affiliation
  • Grossman RL; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Abel B; Genomic Health, Redwood City, California, USA.
  • Angiuoli S; Personal Genome Diagnostics, Baltimore, Maryland, USA.
  • Barrett JC; AstraZeneca, Waltham, Massachusetts, USA.
  • Bassett D; Celgene, Seattle, Washington, USA.
  • Bramlett K; Thermo Fisher Scientific, Austin, Texas, USA.
  • Blumenthal GM; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, USA.
  • Carlsson A; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
  • Cortese R; Seven Bridges, Cambridge, Massachusetts, USA.
  • DiGiovanna J; Seven Bridges, Cambridge, Massachusetts, USA.
  • Davis-Dusenbery B; Seven Bridges, Cambridge, Massachusetts, USA.
  • Dittamore R; Epic Research and Diagnostics, San Diego, California, USA.
  • Eberhard DA; Genomic Health, Redwood City, California, USA.
  • Febbo P; Genomic Health, Redwood City, California, USA.
  • Fitzsimons M; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Flamig Z; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Godsey J; Thermo Fisher Scientific, Waltham, Massachusetts, USA.
  • Goswami J; Thermo Fisher Scientific, Carlsbad, California, USA.
  • Gruen A; Seven Bridges, Cambridge, Massachusetts, USA.
  • Ortuño F; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Han J; Genomic Health, Redwood City, California, USA.
  • Hayes D; University of Michigan, Ann Arbor, Michigan, USA.
  • Hicks J; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
  • Holloway D; Seven Bridges, Cambridge, Massachusetts, USA.
  • Hovelson D; University of Michigan, Ann Arbor, Michigan, USA.
  • Johnson J; AstraZeneca, Waltham, Massachusetts, USA.
  • Juhl H; Indivumed GmbH, Hamburg, Germany.
  • Kalamegham R; Genentech, Washington, District of Columbia, USA.
  • Kamal R; Omicia, Oakland, California, USA.
  • Kang Q; University of Michigan, Ann Arbor, Michigan, USA.
  • Kelloff GJ; Office of the Director, National Cancer Institute, Bethesda, Maryland, USA.
  • Klozenbuecher M; Omicia, Oakland, California, USA.
  • Kolatkar A; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
  • Kuhn P; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
  • Langone K; Genomic Health, Redwood City, California, USA.
  • Leary R; Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA.
  • Loverso P; Personal Genome Diagnostics, Baltimore, Maryland, USA.
  • Manmathan H; Seven Bridges, Cambridge, Massachusetts, USA.
  • Martin AM; Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
  • Martini J; Pfizer, San Diego, California, USA.
  • Miller D; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Mitchell M; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Morgan T; University of Michigan, Ann Arbor, Michigan, USA.
  • Mulpuri R; Provista Diagnostics Inc., New York, New York, USA.
  • Nguyen T; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
  • Otto G; Foundation Medicine, Cambridge, Massachusetts, USA.
  • Pathak A; Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA.
  • Peters E; Genentech, South San Francisco, California, USA.
  • Philip R; Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA.
  • Posadas E; CytoLumina, Inc., Los Angeles, California, USA.
Clin Pharmacol Ther ; 101(5): 589-592, 2017 May.
Article in En | MEDLINE | ID: mdl-28187516
ABSTRACT
The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood Profiling Atlas in Cancer (BloodPAC) Project. BloodPAC will aggregate, make freely available, and harmonize for further analyses, raw datasets, relevant associated clinical data (e.g., clinical diagnosis, treatment history, and outcomes), and sample preparation and handling protocols to accelerate the development of blood profiling assays.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atlases as Topic / Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2017 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atlases as Topic / Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2017 Document type: Article Affiliation country: